TATX 06
Alternative Names: TATX-06Latest Information Update: 09 Feb 2023
At a glance
- Originator Talem Therapeutics
- Class Antivirals; Bispecific antibodies
- Mechanism of Action Virus internalisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Discontinued COVID 2019 infections
Most Recent Events
- 08 Feb 2023 Discontinued for COVID-2019 infections in USA (Parenteral) (Talem therapeutics pipeline, February 2023)
- 02 Nov 2022 TATX 06 is available for licensing as of 02 Nov 2022. https://talemtherapeutics.com/ (Talem Therapeutics website, November 2022)
- 02 Nov 2022 Early research in COVID-19 infections in USA (Parenteral) (Talem Therapeutics website, November 2022)